Sugi Predict

Sugi Predict / Compounds / Sovatelitide

Sovatelitide

Sovatelitide

SCHEMBL26929010

CC[C@H](C)[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O)C(C)C)C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O)[C@@H](C)CC

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 15/20 0.63
▸ ECE1 P42892 1/20 0.63
▸ MUS81 Q96NY9 1/20 0.63
▸ IL23R Q5VWK5 5/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sovatelitide SCHEMBL29405690 0.90 GLP1R (0.61) GLP1R
SCHEMBL23522695 0.85 IL23R (0.65) GLP1RECE1MUS81IL23R
SCHEMBL29972957 0.85 GLP1R (0.62) GLP1R
SCHEMBL29492081 0.83 GLP1R (0.71) GLP1RECE1MUS81
SCHEMBL29973096 0.83 GLP1R (0.60) GLP1R
SCHEMBL30887557 0.82 IL23R (0.60) GLP1RIL23R
SCHEMBL26802791 0.81 IL23R (0.68) GLP1RECE1MUS81IL23R
SCHEMBL31666092 0.81 GLP1R (0.61) GLP1RECE1MUS81IL23R
SCHEMBL31666091 0.81 GLP1R (0.61) GLP1RECE1MUS81IL23R
Enfuvirtide SCHEMBL34310 0.81 GLP1R (0.69) GLP1RECE1MUS81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4713094-A2 PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF HEARING LOSS Pharmazz, Inc. (US) 2026-03-25 — — EP disclosed
US-20250325636-A1 USE OF ENDOTHELIN RECEPTOR TYPE B AGONISTS FOR THE TREATMENT OF AORTIC VALVE STENOSIS INST NAT SANTE RECH MED (FR) 2025-10-23 — — US disclosed
EP-4536198-A1 USE OF ENDOTHELIN RECEPTOR TYPE B AGONISTS FOR THE TREATMENT OF AORTIC VALVE STENOSIS Institut National de la Santé et de la Recherche Médicale (FR) 2025-04-16 — — EP disclosed
WO-2024238297-A2 PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF HEARING LOSS PHARMAZZ, INC. (US) 2024-11-21 — — WO disclosed
WO-2023237661-A1 USE OF ENDOTHELIN RECEPTOR TYPE B AGONISTS FOR THE TREATMENT OF AORTIC VALVE STENOSIS Institut National de la Santé et de la Recherche Médicale (FR) 2023-12-14 — — WO disclosed
Send feedback